FeesSafety
Pluang+

JonesTrading appoints Stephen Holowesko as Managing Director to boost Outsourced Trading growth.

Market News
04 Nov 2026, 18:35 WIB
PRNewsWire
View Source
Bullish
JonesTrading appoints Stephen Holowesko as Managing Director to boost Outsourced Trading growth.

JonesTrading Institutional Services has named Stephen Holowesko, CFA, as Managing Director of its Outsourced Trading team, enhancing its expertise amid growing demand from institutional clients. Holowesko brings extensive experience from hedge funds and Goldman Sachs, supporting JonesTrading's strategy to expand its Outsourced Trading business. This move underscores the firm's commitment to investing in senior talent to meet complex client needs and strengthen its market position. JonesTrading continues to grow its platform as a leading provider of institutional trading and liquidity solutions.

JonesTrading's expansion of its Outsourced Trading team is noted here alongside Pluang's Financials sector market data. For readers following Financials, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: out of 142 priced US Financials stocks, 126 rose and 16 fell. Notable movers include RIOT at USD 15.68 with a +11.80% change and a typical hold time of 18 days, GLXY at USD 14.89 down -11.53% with a hold time of 8 days, and AVAT at USD 0.96 up +9.99% with a hold time of 15 days. Pluang order activity shows mixed buy/sell interest across these names.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
54 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
54 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
54 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
54 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
54 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App